Merck & Co. Inc. is nearing approval of its two-drug direct-acting antiviral combo for hepatitis C heading into the American Association for the Study of Liver Disease conference, but its commercial strategy seems already to be looking past the so-called "doublet" to several therapeutic improvements that a triple-combination therapy in Phase II could offer.
Merck's HCV Strategy Might Be: Get To Market, Then Improve Incrementally
Labeling for intravenous drug users with hepatitis C might be an important niche indication while Merck gets triple combination NDA ready.
More from Clinical Trials
More from R&D
• By
Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.
• By
A new European initiative will help trial sponsors better understand whether digitization and decentralized clinical trials of drugs generate less carbon than traditional methods.
• By
A first-of-its-kind review of clinical trial applications submitted to the UK medicines regulator, the MHRA, shows there is a concentration of research in certain disease areas and identifies opportunities to enhance the representation of specific patient groups.